Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study

Bristol-Myers Squibb (BMS)

Status: Withdrawn

Conditions: Rheumatoid Arthritis

Treatments: Drug: Orencia

Study type: Observational

Funder types: Industry

Identifiers

NCT01694693

IM101-364

Details and patient eligibility

About

Database analysis:

• To describe how Orencia is prescribed in France in Rheumatoid Arthritis (RA)
• To describe joint population of Orencia
• To assess the impact of the treatment on health status of the treated population as assessed by morbid-mortality criteria
• To describe therapeutic strategies and use of health services

Full description

• Observational Model: Historic cohort generated from Société Française de Rhumatologie's (SFR) Orencia and Rheumatoid Arthritis (ORA) registry
• Sampling Method: all physicians and sites taking in charge RA patients received an invitation mailing to participate to ORA
• Minimum Age: 18 years old at Orencia initiation

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Adult outpatients, male or female aged ≥ 18 years old
• Diagnosed with a rheumatoid arthritis according to ACR criteria
• Treated with Orencia according to usual practice conditions from June 1st 2007
• Agreeing to participate

Exclusion Criteria:

• Patients treated by Orencia in the context of clinical trials

Trial design

0 participants in 1 patient group

RA patients treated by Orencia

Description:

RA patients treated by Orencia according to usual practice from June 1st 2007

Treatment:

Drug: Orencia